Drugs / L-DOS47
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02309892 | Apr 2015 → Aug 2019 | non-small cell lung carcinoma | Helix BioPharma Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04203641 | Dec 2019 → Oct 2024 | malignant pancreatic neoplasm | Helix BioPharma Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02340208 | May 2012 → Aug 2017 | non-small cell lung carcinoma | Helix BioPharma Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03891173 | Feb 2019 → May 2020 | lung adenocarcinoma | Helix BioPharma Corporation | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2025-08-13 | Helix BioPharma Corporation | Results Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC helixbiopharma.com ↗
The Phase I/II open-label study demonstrated that L-DOS47 was well tolerated at doses up to 13.55 µg/kg. |
| 2019-07-09 | Helix BioPharma Corporation | Regulatory Helix BioPharma Crop. Submits L-DOS47 IND Application with U.S. FDA For Pancreatic Cancer helixbiopharma.com ↗
Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for approval to initiate a Phase I/II clinical study protocol with L-DOS47 |
| 2019-04-30 | Helix BioPharma Corporation | Results L-DOS47 Phase II Randomized Study Advances to Second Cohort helixbiopharma.com ↗
No serious adverse events or dose limiting toxicities were observed. |
| 2018-04-10 | Helix BioPharma Corporation | Regulatory Helix BioPharma Corp. Announces Regulatory Approval to Dose Patients in a Phase II Randomized Study of L-DOS47 with Vinorelbine and Cisplatin helixbiopharma.com ↗ |
| 2016-03-08 | Helix BioPharma Corporation | Regulatory Helix BioPharma Corp. Reports on Advancement of Its L-DOS47 Phase I/II Study in Poland helixbiopharma.com ↗ |
| 2014-05-14 | Helix BioPharma Corporation | Regulatory Helix BioPharma Corp Submits L-DOS47 Clinical Trial Application with Health Canada helixbiopharma.com ↗
Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recent submission of a Clinical Trial Application with Health Canada for approval to initiate a Phase I clinical trial with L-DOS47. |
| 2014-04-22 | Helix BioPharma Corporation | Regulatory Helix BioPharma Corp. Receives U.S. FDA Approval to Initiate a Clinical Trial of L-DOS47 helixbiopharma.com ↗
Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received approval from the U.S. Food and Drug Administration (“FDA”), to initiate a Phase I clinical trial with L-DOS47. |
| 2014-04-03 | Helix BioPharma Corporation | Regulatory Helix BioPharma Corp. Submits L-DOS47 Investigational New Drug Application with U.S. Food and Drug Administration helixbiopharma.com ↗ |
All press releases naming this drug 17 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-DOS47 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03891173 ↗ |
| Modality | Other / unclassified | “A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47” NCT02309892 ↗ |
| Route | Intravenous | “for iv injection” NCT03891173 ↗ |